Hybrid-Designed Inhibitors of p38 MAP Kinase UtilizingN-Arylpyridazinones
- 20 December 2002
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 46 (3), 349-352
- https://doi.org/10.1021/jm025585h
Abstract
Imidazo[1,2-a]pyridyl N-arylpyridazinones were hybridized from the classic pyridinylimidazoles and the more recent dual hydrogen bond acceptors, resulting in a new structural class of selective p38 MAP kinase inhibitors.Keywords
This publication has 13 references indexed in Scilit:
- Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinaseBioorganic & Medicinal Chemistry Letters, 2003
- MAP KinasesChemical Reviews, 2001
- TUMOUR NECROSIS FACTOR AS A THERAPEUTIC TARGET IN RHEUMATOID ARTHRITIS AND OTHER CHRONIC INFLAMMATORY DISEASES: THE CLINICAL EXPERIENCE WITH INFLIXIMAB (REMICADE™)International Journal Of Clinical Practice, 2001
- New inhibitors of p38 kinaseExpert Opinion on Therapeutic Patents, 2000
- Design and Synthesis of Potent, Selective, and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein KinaseJournal of Medicinal Chemistry, 1999
- Molecular Basis for p38 Protein Kinase Inhibitor SpecificityBiochemistry, 1998
- Characterization of the Structure and Function of the Fourth Member of p38 Group Mitogen-activated Protein Kinases, p38δJournal of Biological Chemistry, 1997
- Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinaseBioorganic & Medicinal Chemistry, 1997
- Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial.Heart, 1996
- Synthesis and properties of aryl-1,3-dioxo carboxylic acidsThe Journal of Organic Chemistry, 1990